- Conditions
- Irritable Bowel Syndrome
- Interventions
- Eluxadoline, Placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 257
- States / cities
- Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 11,819
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bipolar Disorder
- Interventions
- iloperidone
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Breast Cancer, Osteoporosis
- Interventions
- calcium carbonate, vitamin D, risedronate sodium, placebo
- Dietary Supplement · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 198
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 124 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Lower Back Pain
- Interventions
- Carisoprodol SR 700 mg, Carisoprodol SR 500 mg, Placebo
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Hueytown, Alabama + 62 more
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- ALIS, Azithromycin, Ethambutol, ELC
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Fresno, California • San Diego, California + 24 more
- Conditions
- Solid Cancers
- Interventions
- Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Stanford, California • Detroit, Michigan • Houston, Texas
- Conditions
- Multiple Sclerosis, Fatigue, Insomnia
- Interventions
- Suvorexant, Placebo
- Drug
- Lead sponsor
- Theodore R. Brown, MD MPH
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus
- Interventions
- GSK2248761 WBM Capsule, GSK2248761 WBM Tablet Formulation 1, GSK2248761 WBM Tablet Formulation 2, GSK2248761 WBM Tablet Formulation 3, GSK2248761 WBM Tablet
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Parkinson's Disease
- Interventions
- IPX066, IR CD-LD
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- VX-222, telaprevir, ribavirin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more
- Conditions
- Healthy Subjects (HS)
- Interventions
- TNX-102 SL
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 1356, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • National City, California + 9 more
- Conditions
- Healthy Volunteers
- Interventions
- Tafenoquine, Placebo
- Drug · Other
- Lead sponsor
- 60 Degrees Pharmaceuticals LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Colorado Springs, Colorado • McAllen, Texas
- Conditions
- Complex Regional Pain Syndromes, Back Pain
- Interventions
- Experimental: Virtual Reality Guided Imagery, Active Comparator: Audio Only Guided Imagery
- Device · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Schizophrenia
- Interventions
- Risperidone, Placebo, LY2140023
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 19
- States / cities
- Escondido, California • Garden Grove, California • Paramount, California + 16 more
- Conditions
- Chronic Heart Failure
- Interventions
- Enalapril, Aliskiren
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 58
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 51 more
- Conditions
- T2DM (Type 2 Diabetes Mellitus)
- Interventions
- ASC30 tablets, Placebo
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 8
- States / cities
- Riverside, California • San Jose, California • Denver, Colorado + 4 more
- Conditions
- Primary Arteriovenous Fistula Failure
- Interventions
- Atorvastatin 40mg, Placebo
- Drug · Other
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Weight Regain Post Bariatric Surgery
- Interventions
- Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
- Conditions
- Smoking Cessation, Smoking Behaviors, Smoking
- Interventions
- Varenicline, Placebo oral tablet
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Rheumatoid Arthritis
- Interventions
- VX-509, VX-509 matching placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 28 more